Stryker Corp. (NYSE:SYK) VP Yin C. Becker sold 12,000 shares of the company’s stock in a transaction dated Wednesday, October 12th. The shares were sold at an average price of $114.03, for a total value of $1,368,360.00. Following the completion of the sale, the vice president now directly owns 28,939 shares of the company’s stock, valued at $3,299,914.17. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Stryker Corp. (NYSE:SYK) opened at 113.58 on Friday. The firm has a market cap of $42.51 billion, a PE ratio of 26.78 and a beta of 0.72. The company has a 50-day moving average price of $115.21 and a 200-day moving average price of $114.05. Stryker Corp. has a one year low of $86.68 and a one year high of $123.55.

Stryker Corp. (NYSE:SYK) last released its earnings results on Thursday, July 21st. The medical technology company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.02. The firm earned $2.84 billion during the quarter, compared to the consensus estimate of $2.79 billion. Stryker Corp. had a return on equity of 23.61% and a net margin of 15.33%. Equities analysts predict that Stryker Corp. will post $5.76 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Stryker Corp. (NYSE:SYK)

The company also recently announced a quarterly dividend, which will be paid on Monday, October 31st. Shareholders of record on Friday, September 30th will be given a $0.38 dividend. The ex-dividend date of this dividend is Wednesday, September 28th. This represents a $1.52 dividend on an annualized basis and a yield of 1.34%. Stryker Corp.’s dividend payout ratio (DPR) is 35.85%.

A number of analysts have weighed in on the company. Canaccord Genuity reaffirmed a “buy” rating and set a $130.00 price objective on shares of Stryker Corp. in a research report on Sunday, July 24th. SunTrust Banks Inc. assumed coverage on Stryker Corp. in a research report on Thursday. They set a “buy” rating for the company. JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $119.00 price objective on shares of Stryker Corp. in a research report on Friday, July 22nd. Piper Jaffray Cos. increased their price objective on Stryker Corp. from $120.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, July 22nd. Finally, Credit Suisse Group AG reaffirmed an “outperform” rating and set a $124.00 price objective (up from $110.00) on shares of Stryker Corp. in a research report on Tuesday, July 19th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $114.91.

A number of large investors have recently added to or reduced their stakes in the company. Private Trust Co. NA increased its stake in Stryker Corp. by 7.7% in the third quarter. Private Trust Co. NA now owns 20,232 shares of the medical technology company’s stock worth $2,355,000 after buying an additional 1,445 shares during the period. Renaissance Investment Group LLC increased its stake in Stryker Corp. by 8.2% in the third quarter. Renaissance Investment Group LLC now owns 2,970 shares of the medical technology company’s stock worth $346,000 after buying an additional 225 shares during the period. Cohen Capital Management Inc. increased its stake in Stryker Corp. by 0.8% in the third quarter. Cohen Capital Management Inc. now owns 92,400 shares of the medical technology company’s stock worth $10,756,000 after buying an additional 700 shares during the period. Private Bank & Trust Co. increased its stake in Stryker Corp. by 0.5% in the third quarter. Private Bank & Trust Co. now owns 4,222 shares of the medical technology company’s stock worth $492,000 after buying an additional 23 shares during the period. Finally, MSI Financial Services Inc increased its stake in Stryker Corp. by 5.2% in the third quarter. MSI Financial Services Inc now owns 11,184 shares of the medical technology company’s stock worth $1,302,000 after buying an additional 556 shares during the period. Hedge funds and other institutional investors own 75.49% of the company’s stock.

Stryker Corp. Company Profile

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

5 Day Chart for NYSE:SYK

Receive News & Stock Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related stocks with our FREE daily email newsletter.